



ERS Satellites:  
**SEVERE ASTHMA**  
12 April 2018

## Details for presentation topics

### 1) Definition, epidemiology and impact of severe asthma:

*the definition of severe asthma has evolved over time (within GINA; over ATS 2002 towards ERS/ATS definition 2014); epidemiology of (refractory) severe asthma versus uncontrolled asthma; impact of severe asthma on individual patients and societies / health care systems;*

### 2) Pathogenesis of severe asthma and its natural history:

*novel insights into different pathways leading to eosinophilic versus non-eosinophilic airway inflammation in asthma; innate versus adaptive (mucosal) immunity; chronic airway remodeling;*

### 3) Differential diagnosis and phenotyping of severe asthma:

*from uncontrolled asthma towards refractory severe asthma;*

### 4) Current and future biomarkers in severe asthma:

*diagnostic, prognostic and/or theragnostic biomarkers in blood, sputum and exhaled air; role of imaging biomarkers (for endotyping in clinical practice or as intermediate surrogate endpoint in clinical trials);*

### 5) Co-morbidities in severe asthma across the life course:

*Four clusters of co-morbidities can be defined in severe asthma: a/ as integral part of severe asthma phenotypes (e.g. nasal polyposis in late-onset severe eosinophilic asthma), b/ as complication of long-lasting disease (fixed airflow limitation; bronchiectasis), c/ as complication of treatment (osteoporosis due to chronic treatment of OCS), or d/ as effect modifiers (sleep apnea syndrome or symptomatic gastro-oesophageal reflux, aggravating severe asthma);*

### 6) What is different about severe asthma in children and adults?

*Prognostic and therapeutic strategies;*

### 7) Anti-eosinophil and anti-type 2 directed targeted therapies:

*targeted therapies of type 2 severe asthma (beyond direct anti-eosinophil therapies): biologics = anti-IgE (omalizumab), anti-IL5 (mepolizumab, reslizumab) and anti-IL5R (benralizumab); anti-IL4R (dupilumab), anti-TSLP, anti-IL33 (R), ...; optimal patient selection;*

### 8) Treatment of non-type 2 severe asthma:

*treatment of non-type 2 severe asthma (severe asthma due to neutrophilic or pauci-granulocytic inflammation): biologics (e.g. anti-IL17 (R) monoclonal antibodies); oral treatments (e.g. macrolides); inhaled therapies (LAMA / tiotropium; triple therapy) and interventional bronchoscopy (e.g. bronchial thermoplasty).*

# Programme

<b>09:00 – 09:10</b>	<b>Opening of the ERS Satellite Symposium 2018</b> Guy Brusselle (BE) & Stephen Holgate (UK)
<b>09:15 – 10:30</b>	<b>Basics</b>
09:15 – 09:40	Live from Rome: Definition, epidemiology and impact of severe asthma
09:40 – 09:50	Questions
	Chair: Walter Canonica (IT)      Speaker: Pierluigi Paggiaro (IT)
09:55 – 10:20	Live from Brussels: Pathogenesis of severe asthma and its natural history
10:20 – 10:30	Questions
	Chair: Guy Brusselle (BE)      Speaker: Bart Lambrecht (BE)

## Coffee Break 25 minutes

<b>10:55 – 12:10</b>	<b>Diagnosis and management (Part I)</b>
10:55 – 11:20	Live from Paris: Differential diagnosis and phenotyping
11:20 – 11:30	Questions
	Chair: Marc Humbert (FR)      Speaker: Pascal Chanez (FR)
11:35 – 12:00	Live from London: Current and future biomarkers in severe asthma
12:00 – 12:10	Questions
	Chair: Stephen Holgate (UK)      Speaker: Chris Brightling (UK)

## Lunch and closed session with local faculty 1 hour 40 minutes

<b>13.50 – 15:25</b>	<b>Diagnosis and management (Part II)</b>
13.50 – 14:15	Live from Amsterdam: Co-morbidities in severe asthma across the life course
14:15 – 14:25	Questions
	Chair: Marielle Pijnenburg (NL)      Speaker: Elisabeth Bel (NL)

## Coffee Break 25 Minutes

14.50 – 15:15	Live from Stockholm: What is different about severe asthma in children and adults?
15:15 – 15:25	Questions
	Chair: Sven-Erik Dahlen (SE)      Speaker: Gunilla Hedlin (SE)
<b>15:30 – 16:55</b>	<b>Treatment</b>
15:30 – 15:55	Live from Berlin: Anti-eosinophil and anti-type 2 directed targeted therapies
15:55 – 16:05	Questions
	Chair: Klaus Rabe (DE)      Speaker: Roland Buhl (DE)
16:10 – 16:45	Live from Madrid: Stratification and treatment of non-type 2 severe asthma
16:45 – 16:55	Questions
	Chair: Alvar Agusti (SP)      Speaker: Luis Perez de Llano (SP)
<b>17:00 – 17:10</b>	<b>Closing of the ERS Satellite Symposium 2018</b> Guy Brusselle (BE) & Stephen Holgate (UK)

# Venues

City	Address	
Amsterdam	Novotel City Amsterdam Hotel	Europaboulevard 10, 1083 AD, Amsterdam
Berlin	Novotel Berlin Am Tiergarten Hotel	Strasse des 17 Juni 106-108, 10623 Berlin
Brussels	Radisson Blu Royal Hotel	Rue du Faussé aux Loups 47, 1000 Brussels
London	Park Plaza Victoria Hotel	239 Vauxhall Bridge Road, London, SW1V 1EQ
Madrid	NH Principe de Vergara Hotel	Calle del Príncipe de Vergara 92, Madrid
Paris	Novotel Paris Bercy Hotel	5 Rue de Bercy, 75012 Paris
Rome	Eurostars Roma Aeterna Hotel	Via Casilina 125, Roma 00176
Stockholm	Nobel Forum	Nobels väg 1, 171 77, Solna